SetPoint Medical is a biomedical technology company developing neuromodulation therapies for patients with inflammatory autoimmune diseases, such as rheumatoid arthritis and Crohn's Disease.
The company's scientific platform is based on the Inflammatory Reflex—the natural mechanism by which the central nervous system regulates the immune system. SetPoint co-founder Kevin Tracey discovered the Inflammatory Reflex pathway, publishing his findings in the journal Nature in May 2000.
SetPoint's approach uses vagus nerve stimulation to activate the Inflammatory Reflex. Published literature suggests the Inflammatory Reflex produces a potent systemic anti-inflammatory effect. The company's novel platform consists of an implantable miniature neuromodulation device, wireless charger and iPad control application.
SetPoint has completed a first-in-human open-label proof-of-concept trial in rheumatoid arthritis. The study helps validate neuromodulation as a breakthrough approach to treating autoimmune inflammatory diseases. SetPoint's approach is designed to supplement the body's natural Inflammatory Reflex by providing 'built-in' therapy at a lower cost and is intended to improve safety compared with drugs or biologic solutions.
SetPoint is headquartered in Valencia, Ca., and investors in the company include Morgenthaler Ventures, Foundation Medical Partners, Topspin Partners, Boston Scientific, Covidien and
Action Potential Venture Capital.